.jpg)
.png)
All
Historically, familial hypercholesterolemia (FH), remains an underdiagnosed and undertreated disease. It is estimated that 90% of individuals with FH remain undiagnosed in the United States.(1) FH patients have ten to twenty-fold higher risk of cardiovascular disease. However, cardiovascular risk... more
The National Lipid Association (NLA) released on Wednesday the results of its survey on the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor prescription approval process.
Dr. Harold E. Bays, Louisville resident and SELA President, was recently awarded the President’s Service Award at the National Lipid Association’s 2015 Annual Sessions. This award recognizes an individual for service and dedication to the NLA, and advancing the development of the specialty of... more
The Foundation of the NLA did something a little different this year – instead of hosting a black-tie gala event, we opted for a more casual affair, filled with light bites and vintage arcade games! The evening was full of good conversation, and friendly competition. We appreciate those who made it... more
Esperion has announced that NEXLETOL™ (bempedoic acid) is now available in pharmacies in the United States. NEXLETOL is an oral, once-daily, tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH... more
Pediatric hypertriglyceridemia (fasting triglycerides ≥ 130 mg/dL) was identified by routine screening in a healthy 14-year-old male. He was subsequently referred to our pediatric lipid clinic for evaluation. A fasting lipid profile confirmed hypertriglyceridemia: total cholesterol (TC): 136... more
Does your 2015 calendar include the NLA Scientific Sessions from June 11 to 14? This annual meeting will bring more than 550 lipidologists and healthcare professionals to the Palmer House Hotel in Chicago to learn about the latest research on emerging topics in lipids and other... more
With recent guideline changes, it is common for clinicians to field questions regarding aspirin therapy. This article is intended to help clinicians apply an individualized and evidence-based approach to the appropriate use of aspirin in specific at-risk patient populations. Aspirin’s Role in... more
.color-blue{ color: #23527c; } Who am I? This is the essential existential question that everyone needs to ask at some point in life. At the National Lipid Association (NLA), this is a question that we will be asking ourselves over the next few years as our field redefines itself. Is it enough... more
Oct. 25, 2018 Amgen announced on Wednesday, Oct. 24 it is making evolocumab available at a reduced list price in an effort to improve affordability and access for patients. The announcement represents positive news for patients at risk for cardiovascular events. Key outcomes from Amgen’s... more